Bronchial carcinoma: Added benefit of crizotinib not proven

(Institute for Quality and Efficiency in Health Care) The dossier contains no data or no suitable data on ROS1-positive, advanced non-small cell lung cancer. Results on ALK-positive tumors are not applicable.

Source: EurekAlert! - Medicine and Health - January 11, 2017 Category: Global & Universal Source Type: news